BioStock

Prenumeration

Enzymatica’s CEO steps down after four years – summarizes a journey from science to commercialization

2025-11-04 15:13:00

After four years as CEO, Claus Egstrand is leaving his position at Enzymatica. In his final quarterly report, he reflects on the company’s development and the journey that has taken ColdZyme from scientific validation to commercial strength. BioStock contacted Egstrand to get his thoughts.

Read the full article at biostock.se:
https://biostock.se/en/2025/11/enzymaticas-vd-lamnar-efter-fyra-ar-summerar-en-resa-fran-vetenskap-till-kommersialisering/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden